SpyGlass Pharma, Inc.
SGP Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2024–FY2025
Last close · Oct 23, 2026
$28.48
0.9%What SpyGlass Pharma, Inc. does
No business description yet.
- Legal name
- SpyGlass Pharma, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Accession · CIK
- 0001778922-26-000020
0001778922
Revenue and margins
SpyGlass Pharma, Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$33.5M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
SpyGlass Pharma, Inc. returned $1.5M to shareholders in fiscal 2025. The diluted share count rose 24.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably SpyGlass Pharma, Inc. can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $16.3M | $96.4M |
| Current ratio | 2.2x | 12.7x |
| Quick ratio | 2.2x | 12.7x |
| Total assets | $23.3M | $116M |
| Total liabilities | $11.2M | $10.2M |
| Shareholders' equity | −$60.5M | −$98.8M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✓ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | — |
| F-score | — / 3 | — / 6 |
| Accruals ratio | −30.6% | −10.3% |
| Altman Z'' | −19.81 | −9.89 |
2 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Research and development | $20.0M | $29.2M |
| Operating income | −$27.1M | −$41.4M |
| Pretax income | −$29.2M | −$39.9M |
| Income tax | $0.0M | $0.0M |
| Net income | −$29.2M | −$39.9M |
| Diluted EPS | −$16.31 | −$17.98 |
| Diluted shares | 0.00B | 0.00B |
| Cash flow | ||
| Cash from operations | −$22.0M | −$32.7M |
| Capital expenditure | $2.0M | $0.8M |
| Free cash flow | −$24.0M | −$33.5M |
| Depreciation and amortization | $0.3M | $0.6M |
| Stock-based compensation | $1.5M | $2.8M |
| Share buybacks | $0.0M | $1.5M |
| Dividends and buybacks | $0.0M | $1.5M |
| Balance sheet | ||
| Cash and short-term investments | $16.3M | $96.4M |
| Current assets | $17.4M | $109M |
| Current liabilities | $7.8M | $8.6M |
| Property and equipment, net | $2.2M | $2.3M |
| Total assets | $23.3M | $116M |
| Total liabilities | $11.2M | $10.2M |
| Preferred stock | — | $0.0M |
| Shareholders' equity | −$60.5M | −$98.8M |
| Returns | ||
| Return on capital employed | −174.3% | −38.6% |
| Return on assets | −125.1% | −57.3% |
| Growth | ||
| Share count change | — | 24.0% |
| Financial health | ||
| Current ratio | 2.2x | 12.7x |
| Quick ratio | 2.2x | 12.7x |
| Quality scores | ||
| Altman Z'' | −19.8 | −9.9 |
| Accruals ratio | −30.6% | −10.3% |
Source: SEC EDGAR XBRL filings (CIK 0001778922). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.